

<b>GlaxoSmithKline</b> <b>Artwork Information Panel</b>		<b>Item Number:</b> 1000000133894	<b>Manufacturing Site:</b> GSK-ITA-Verona-ITVER	
<b>Market or Pack Owner:</b> *Multi-Market Central-GEXP		<b>Market Trade Name:</b> Zinacef	<b>Colour Standard Reference Number:</b> N/A	
<b>Technical Reference No(s):</b> D94225LEA <small>(do NOT include the technical reference doc(s) version no(s).)</small>		<b>Printing Process:</b> N/A	<b>Substrate:</b> N/A	
<b>Colours</b>	<b>K</b>			
	<b>Total: 1</b>			
<b>Varnishes</b>				
	<b>Total: 0</b>			
<b>Special Finishes</b>				
	<b>Total: 0</b>			<b>RSC A/W Version: 1</b>

Artwork copyright is the property of the GlaxoSmithKline Group of Companies  
All suppliers providing a service to GSK for printed components of any description must ensure that they have a licence for all fonts/software used in conjunction with GSK artwork. The distribution and use of fonts/software without a licence constitutes an intellectual property infringement. GSK will not accept any liability for the breach of third party intellectual property rights by printed component suppliers. The GSK certification/audit process requires suppliers to declare that they do not use unlicensed fonts/software and may require the supplier to produce evidence of such licence to GSK.

ATTENTION	ATTENTION	ATTENTION	ATTENTION	ATTENTION	ATTENTION	ATTENTION	ATTENTION	ATTENTION
<b>To Ensure Accurate PDF Viewing and Printing:</b>								
<b>FOR SCREEN VIEWING:</b> Use Adobe Acrobat 7 Professional or Adobe Acrobat Reader, Standard or Professional (higher than 7). <b>Overprint Preview</b> must be activated for accurate on screen viewing.								
<b>FOR PRINTING:</b> Use only Acrobat Professional version 7 or higher. <b>"Apply Overprint Preview"</b> or <b>"Simulate Overprinting"</b> must be activated in the print settings for printing accurate hard copies.								

<b>180 mm Measuring Bar</b>	
If a status identification banner DOES NOT appear on this document, THEN this document has NOT been printed from the Global Pack Management system.	

## IMPORTANT

GSK Market is responsible for this product, its design and content. Ensure the artwork is thoroughly checked, all the text proof-read and approved.

RSC GSK is responsible for site technical requirements and pre-press suitability.

GSK Market is responsible to advise RSC in case changes required impact the followings:

### Formulation

### Tablet embossing

### Storage conditions

### Shelf Life

TEXT SIZE CONTAINED IN THIS ARTWORK		
<b>Body text size: 8.Opt</b>	<b>Leading: 9.5pt</b>	<b>Horizontal Scale: 85%</b>
<b>Smallest text size: 8.Opt</b>	<b>Microtext: No</b>	

## Zinacef™ Cefuroxime sodium

1000000133894

### QUALITATIVE AND QUANTITATIVE COMPOSITION

ZINACEF Injection contains 250 mg, 750 mg, 1 g and 1.5 g of cefuroxime (as cefuroxime sodium).  
ZINACEF MONOVALE™ contains 750 mg and 1.5 g of cefuroxime (as cefuroxime sodium).

### PHARMACEUTICAL FORM

Powder for solution for injection (Injection)  
Powder for solution for infusion (MONOVALE)

### CLINICAL PARTICULARS

#### Indications

ZINACEF is a bactericidal cephalosporin antibiotic which is resistant to most beta-lactamases and is active against a wide range of Gram-positive and Gram-negative organisms.

It is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. Susceptibility to ZINACEF will vary with geography and time and local susceptibility data should be consulted where available (see *Pharmacological properties, Pharmacodynamics*).

#### Indications include:

- respiratory tract infections for example, acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections
- ear, nose and throat infections for example, sinusitis, tonsillitis, pharyngitis and otitis media
- urinary tract infections for example, acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria
- soft-tissue infections for example, cellulitis, erysipelas and wound infections
- bone and joint infections for example, osteomyelitis and septic arthritis
- obstetric and gynaecological infections, pelvic inflammatory diseases
- gonorrhoea particularly when penicillin is unsuitable
- other infections including septicaemia, meningitis and peritonitis
- prophylaxis against infection in abdominal, pelvic, orthopaedic, cardiac, pulmonary, oesophageal and vascular surgery where there is increased risk from infection.

Usually ZINACEF will be effective alone, but when appropriate it may be used in combination with an aminoglycoside antibiotic, or in conjunction with metronidazole (orally or by suppository or injection), especially for prophylaxis in colonic or gynaecological surgery. Where appropriate ZINACEF is effective when used prior to oral therapy with ZINNAT (cefuroxime axetil) in the treatment of pneumonia and acute exacerbations of chronic bronchitis.

#### Dosage and Administration

ZINACEF Injection is for intravenous (i.v.) and/or intramuscular (i.m.) administration.  
ZINACEF MONOVALE is for i.v. infusion only.

ZINACEF is also available as the axetil ester (ZINNAT™) for oral administration. This permits the use of sequential therapy with the same antibiotic, when a change from parenteral to oral therapy is clinically indicated.

No more than 750 mg should be injected at one intramuscular site.

#### GENERAL DOSING RECOMMENDATIONS

##### Adults

Many infections respond to 750 mg three times daily by i.m. or i.v. injection. For more severe infections the dose should be increased to 1.5 g three times daily given i.v. The frequency of administration may be increased to 6-hourly if necessary, giving total daily doses of 3 to 6 g. Where clinically indicated, some infections respond to 750 mg or 1.5 g twice daily (i.v. or i.m.) followed by oral therapy with ZINNAT.

##### Infants and Children

30 to 100 mg/kg/day given as 3 or 4 divided doses. A dose of 60 mg/kg/day is appropriate for most infections.

##### Neonates

30 to 100 mg/kg/day given as 2 or 3 divided doses (see *Pharmacokinetics*).

#### GONORRHOEA

##### Adults

1.5 g as a single dose (as 2 x 750 mg injections given i.m. with different sites e.g. each buttock).

#### MENINGITIS

ZINACEF is suitable for sole therapy of bacterial meningitis due to sensitive strains.

- **Adults:** - 3 g given i.v. every 8 hours.
- **Infants and Children:** - 150 to 250 mg/kg/day given i.v. in 3 or 4 divided doses
- **Neonates:** - the dosage should be 100 mg/kg/day given i.v.

#### PROPHYLAXIS

The usual dose is 1.5 g given i.v. with induction of anaesthesia for abdominal, pelvic and orthopaedic operations. This may be supplemented with two 750 mg i.m. doses 8 and 16 hours later.

In cardiac, pulmonary, oesophageal and vascular operations, the usual dose is 1.5 g given i.v. with induction of anaesthesia, continuing with 750 mg given i.m. three times daily for a further 24 to 48 hours.

In total joint replacement, 1.5 g ZINACEF powder may be mixed dry with each pack of methyl methacrylate cement polymer before adding the liquid monomer.

#### SEQUENTIAL THERAPY

##### Adults

Duration of both parenteral and oral therapy is determined by the severity of the infection and the clinical status of the patient.

##### Pneumonia

1.5 g ZINACEF three times daily or twice daily (given i.v. or i.m.) for 48 to 72 hours, followed by 500 mg twice daily ZINNAT (cefuroxime axetil) oral therapy for 7 to 10 days.

##### Acute exacerbations of chronic bronchitis

750 mg ZINACEF three times daily or twice daily (given i.v. or i.m.) for 48 to 72 hours, followed by 500 mg twice daily ZINNAT (cefuroxime axetil) oral therapy for 5 to 10 days.

#### RENAL IMPAIRMENT

Cefuroxime is excreted by the kidneys. Therefore, as with all such antibiotics, in patients with markedly impaired renal function it is recommended that the dosage of ZINACEF should be reduced to compensate for its slower excretion.

It is not necessary to reduce the standard dose (750 mg to 1.5 g three times daily) until the creatinine clearance falls to 20 ml/min or below.

In adults with marked impairment (creatinine clearance 10 to 20 ml/min) 750 mg twice daily is recommended and with severe impairment (creatinine clearance <10 ml/min) 750 mg once daily is adequate.

For patients on haemodialysis a further 750 mg dose should be given i.v. or i.m. at the end of each dialysis. In addition to parenteral use, ZINACEF can be incorporated into the peritoneal dialysis fluid (usually 250 mg for every 2 litres of dialysis fluid).

For patients in renal failure on continuous arteriovenous haemodialysis or high-flux haemofiltration in intensive therapy units a suitable dosage is 750 mg twice daily. For low-flux haemofiltration follow the dosage recommended under impaired renal function.

#### Contraindications

Hypersensitivity to cephalosporin antibiotics.

#### Warnings and Precautions

Special care is indicated in patients who have experienced an allergic reaction to penicillins or other beta-lactams.

Cephalosporin antibiotics at high dosage should be given with caution to patients receiving concurrent treatment with potent diuretics such as furosemide or aminoglycosides, as renal impairment has been reported with these combinations. Renal function should be monitored in these patients, the elderly, and those with pre-existing renal impairment (see *Dosage and Administration*).

As with other therapeutic regimens used in the treatment of meningitis, mild-to-moderate hearing loss has been reported in a few paediatric patients treated with ZINACEF. Persistence of positive cerebral spinal fluid (CSF) cultures of *Haemophilus influenzae* at 18-36 hours has also been noted with ZINACEF injection, as well as with other antibiotic therapies; however, the clinical relevance of this is unknown.

As with other antibiotics, use of ZINACEF may result in the overgrowth of *Candida*. Prolonged use may also result in the overgrowth of other non-susceptible organisms (e.g. enterococci and *Clostridium difficile*), which may require interruption of treatment.

Pseudomembranous colitis has been reported with the use of antibiotics and may range in severity from mild to life-threatening. Therefore, it is important to consider its diagnosis in patients who develop diarrhoea during or after antibiotic use. If prolonged or significant diarrhoea occurs or the patient experiences abdominal cramps, treatment should be discontinued immediately and the patient investigated further.

With a sequential therapy regime the timing of change to oral therapy is determined by severity of the infection, clinical status of the patient and susceptibility of the pathogens involved. If there is no clinical improvement within 72 hours, then the parenteral course of treatment must be continued.

Refer to the relevant prescribing information for ZINNAT before initiating sequential therapy.

#### Interactions

In common with other antibiotics, ZINACEF may affect the gut flora, leading to lower oestrogen reabsorption and reduced efficacy of combined oral contraceptives.

ZINACEF does not interfere in enzyme-based tests for glycosuria.

Slight interference with copper reduction methods (Benedict's, Fehling's, Clinistest) may be observed. However, this should not lead to false-positive results, as will be experienced with some other cephalosporins.

It is recommended that either the glucose oxidase or hexokinase methods are used to determine blood/plasma glucose levels in patients receiving ZINACEF.

This antibiotic does not interfere in the alkaline picrate assay for creatinine.

#### Pregnancy and Lactation

There is no experimental evidence of embryopathic or teratogenic effects attributable to ZINACEF, but, as with all drugs, it should be administered with caution during the early months of pregnancy. Cefuroxime is excreted in human milk, and consequently caution should be exercised when ZINACEF is administered to a nursing mother.

#### Effects on Ability to Drive and Use Machines

None reported.

#### Adverse Reactions

Adverse drug reactions are very rare (<1/10,000) and are generally mild and transient in nature.

The frequency categories assigned to the adverse reactions below are estimates, as for most reactions suitable data for calculating incidence are not available. In addition the incidence of adverse reactions associated with ZINACEF may vary according to the indication.

Data from clinical trials were used to determine the frequency of very common to rare undesirable effects. The frequencies assigned to all other undesirable effects (i.e., those occurring at <1/1000) were mainly determined using post-marketing data, and refer to a reporting rate rather than a true frequency.

The following convention has been used for the classification of frequency:

Very common ≥1/10,  
Common ≥1/100 to <1/10,  
Uncommon ≥1/1000 to <1/100,  
Rare ≥1/10,000 to <1/1000,  
Very rare <1/10,000.

#### Infections and infestations

Rare Candida overgrowth

#### Blood and lymphatic system disorders

Common Neutropenia, eosinophilia.

Uncommon Leukopenia, decreased haemoglobin concentration, positive Coomb's test.

Rare Thrombocytopenia.

Very rare Haemolytic anaemia.

Cephalosporins as a class tend to be absorbed onto the surface of red cell membranes and react with antibodies directed against the drug to produce a positive Coomb's Test (which can interfere with cross matching of blood) and very rarely haemolytic anaemia.

#### Immune system disorders

Hypersensitivity reactions including

Uncommon Skin rash, urticaria and pruritus.

Rare Drug fever.

Very rare Interstitial nephritis, anaphylaxis, cutaneous vasculitis.

See also Skin and subcutaneous tissue disorders and Renal and urinary disorders.

#### Gastrointestinal disorders

Uncommon Gastrointestinal disturbance.

Very rare Pseudomembranous colitis (see *Warnings and Precautions*).

#### Hepatobiliary disorders

Common Transient rise in liver enzymes.

Uncommon Transient rise in bilirubin.

Transient rises in serum liver enzymes or bilirubin occur, particularly in patients with pre-existing liver disease, but there is no evidence of harm to the liver.

#### Skin and subcutaneous tissue disorders

Very rare Erythema multiforme, toxic epidermal necrolysis and Stevens Johnson Syndrome.

See also Immune system disorders.

#### Renal and urinary disorders

Very rare Elevations in serum creatinine, elevations in blood urea nitrogen and decreased creatinine clearance (see *Warnings and Precautions*).

See also Immune system disorders.

#### General disorders and administration site conditions

Common Injection site reactions which may include pain and thrombophlebitis.

Pain at the intramuscular injection site is more likely at higher doses. However it is unlikely to be a cause for discontinuation of treatment.

#### Overdose

Overdosage of cephalosporins can cause cerebral irritation leading to convulsions. Serum levels of cefuroxime can be reduced by haemodialysis or peritoneal dialysis.

#### PHARMACOLOGICAL PROPERTIES

##### Pharmacodynamics

Cefuroxime is a well characterised and effective antibacterial agent which has bactericidal activity against a wide range of common pathogens, including β-lactamase producing strains. Cefuroxime has good stability to bacterial β-lactamase, and consequently is active against many ampicillin-resistant or amoxicillin-resistant strains.

The bactericidal action of cefuroxime results from inhibition of cell wall synthesis by binding to essential target proteins. The prevalence of acquired resistance is geographically and time dependent and for select species may be very high. Local information on resistance is desirable, particularly when treating severe infections.

#### *In vitro* susceptibility of micro-organisms to Cefuroxime

Where clinical efficacy of cefuroxime has been demonstrated in clinical trials this is indicated with an asterisk (\*).

#### Commonly Susceptible Species

##### Gram-Positive Aerobes:

*Staphylococcus aureus* (methicillin susceptible)\*  
*Coagulase negative staphylococcus* (methicillin susceptible)  
*Streptococcus pyogenes*\*  
Beta-hemolytic streptococci

##### Gram-Negative Aerobes:

*Haemophilus influenzae* including ampicillin resistant strains\*  
*Haemophilus parainfluenzae*\*  
*Moraxella catarrhalis*\*  
*Neisseria gonorrhoea*\* including penicillinase and non-penicillinase producing strains  
*Neisseria meningitidis*  
*Shigella* spp.

##### Gram-Positive Anaerobes:

*Peptostreptococcus* spp.  
*Propionibacterium* spp.

##### Spirochetes:

*Borrelia burgdorferi*\*

#### Organisms for which acquired resistance may be a problem

##### Gram-Positive Aerobes:

*Streptococcus pneumoniae*\*  
Viridans group streptococcus

##### Gram-Negative Aerobes:

*Bordetella pertussis*  
*Citrobacter* spp. not including *C. freundii*  
*Enterobacter* spp. not including *E. aerogenes* and *E. cloacae*  
*Escherichia coli*\*  
*Klebsiella* spp. including *K. pneumoniae*\*  
*Proteus mirabilis*  
*Proteus* spp. not including *P. penneri* and *P. vulgaris*  
*Providencia* spp.  
*Salmonella* spp.

##### Gram-Positive Anaerobes:

*Clostridium* spp. not including *C. difficile*

##### Gram-Negative Anaerobes:

*Bacteroides* spp. not including *B. fragilis*  
*Fusobacterium* spp.

#### Inherently resistant organisms

##### Gram-Positive Aerobes:

*Enterococcus* spp. including *E. faecalis* and *E. faecium*  
*Listeria monocytogenes*

##### Gram-Negative Aerobes:

*Acinetobacter* spp.  
*Burkholderia cepacia*  
*Campylobacter* spp.  
*Citrobacter freundii*  
*Enterobacter aerogenes*  
*Enterobacter cloacae*  
*Morganella morganii*  
*Proteus penneri*  
*Proteus vulgaris*  
*Pseudomonas* spp. including *P. aeruginosa*  
*Serratia* spp.  
*Stenotrophomonas maltophilia*

##### Gram-Positive Anaerobes:

*Clostridium difficile*

##### Gram-Negative Anaerobes:

*Bacteroides fragilis*

##### Others:

*Chlamydia* species  
*Mycoplasma* species  
*Legionella* species

#### Pharmacokinetics

Peak levels of cefuroxime are achieved within 30 to 45 minutes after i.m. administration. Protein binding has been variously stated as 33 - 50% depending on the methodology used.

Concentrations of cefuroxime in excess of the minimum inhibitory levels for common pathogens can be achieved in bone, synovial fluid and aqueous humour. Cefuroxime passes the blood-brain barrier when the meninges are inflamed.

Cefuroxime is not metabolised and is excreted by glomerular filtration and tubular secretion. The serum half-life after either i.m. or i.v. injection is approximately 70 minutes.

In the first weeks of life the serum half-life of cefuroxime can be 3 to 5 times that in the adult.

Concurrent administration of probenecid prolongs the excretion of the antibiotic and produces an elevated peak serum level. There is an almost complete recovery (85 to 90%) of unchanged cefuroxime in urine within 24 hours of administration. The major part is excreted in the first 6 hours.

Serum levels of cefuroxime are reduced by dialysis.

#### Pre-clinical Safety Data

No additional data of relevance.

#### PHARMACEUTICAL PARTICULARS

##### List of Excipients

None.

Each 750 mg vial contains 42 mg sodium (1.8 mEq).

##### Incompatibilities

ZINACEF should not be mixed in the syringe with aminoglycoside antibiotics.

The pH of 2.74% w/v Sodium Bicarbonate Injection BP considerably affects the colour of the solution and therefore this solution is not recommended for the dilution of ZINACEF. However, if required, for patients receiving Sodium Bicarbonate Injection by infusion ZINACEF may be introduced into the tube of the giving set.

##### Shelf-Life

The expiry date of the powder is indicated on the packaging.

Reconstituted suspensions of ZINACEF for i.m. injection and aqueous solutions for direct i.v. injection retain their potency for 5 hours if kept below 25 °C and for 48 hours if refrigerated.

##### Special Precautions for Storage

Protect from light.

Some increase in the colour of prepared solutions and suspensions of ZINACEF may occur on storage.

##### Nature and Contents of Container

As registered locally.